Trihexyphenidyl
Trihexyphenidyl (trihexyphenidyl) is a small molecule pharmaceutical. Trihexyphenidyl was first approved as Artane on 1982-01-01. It is used to treat drug-induced abnormalities and parkinson disease in the USA. The pharmaceutical is active against muscarinic acetylcholine receptor M1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Trihexyphenidyl (discontinued: Artane, Tremin, Trihexyphenidyl)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Trihexyphenidyl hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ARTANE | Lederle Laboratories | N-006773 DISCN | 1982-01-01 | 4 products |
| ARTANE | Lederle Laboratories | N-012947 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| trihexyphenidyl hydrochloride | ANDA | 2026-07-23 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| parkinson disease | EFO_0002508 | D010300 | G20 |
| drug-induced abnormalities | — | D000014 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
9 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dystonic disorders | D020821 | — | G24 | 1 | 1 | — | 1 | — | 3 |
| Cerebral palsy | D002547 | — | G80 | 1 | — | — | 1 | — | 2 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | 1 | 1 | 2 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | — | 1 | 1 | 2 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | 1 | — | 1 |
| Neuralgia | D009437 | EFO_0009430 | — | — | — | — | 1 | — | 1 |
| Muscle spasticity | D009128 | — | — | — | — | — | 1 | — | 1 |
| Deglutition disorders | D003680 | — | R13.1 | — | — | — | 1 | — | 1 |
| Sialorrhea | D012798 | — | K11.7 | — | — | — | 1 | — | 1 |
| Hyperalgesia | D006930 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dystonia | D004421 | — | — | 1 | 1 | — | — | 1 | 3 |
| Torticollis | D014103 | — | F45.8 | — | 1 | — | — | 1 | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | 1 | — | — | — | — | 1 |
| Basal ganglia diseases | D001480 | EFO_0009533 | G23 | 1 | — | — | — | — | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | — | — | — | — | 1 |
| Genetic predisposition to disease | D020022 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dystonia musculorum deformans | D004422 | — | G24.1 | — | — | — | — | 1 | 1 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | — | 1 | 1 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | — | — | 1 | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | — | 1 | 1 |
| Tremor | D014202 | — | R25.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Trihexyphenidyl |
| INN | trihexyphenidyl |
| Description | Trihexyphenidyl, also known as benzhexol and trihex, is an antiparkinsonian agent of the antimuscarinic class. It was approved by the FDA for the treatment of Parkinson's in 2003.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1 |
Identifiers
| PDB | — |
| CAS-ID | 144-11-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1490 |
| ChEBI ID | 9720 |
| PubChem CID | 5572 |
| DrugBank | DB00376 |
| UNII ID | 6RC5V8B7PO (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Trihexyphenidyl
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,463 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,457 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use